Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models

► Targeting glutamate holds great promise for improved treatment of anxiety disorders. ► Anxiolytic activity of mGluR2/3 agonists have achieved the greatest success to date. ► Positive and negative allosteric modulators offer an improved benefit/risk profile. ► Translational models of anxiety and stress disorders respond to glutamate modulation. ► Activity in standard anxiety tests must be replicated in translational animal models.